Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Abi Berger Good direct evidence that the body's inability to clear up cell
debris leads to systemic lupus erythematosus (SLE) has been confirmed
by German scientists.
Cell biologists have confirmed that a lack of DNase1, an enzyme that
degrades DNA, leads to the development of SLE. Their finding is not
only important in understanding the pathogenesis of SLE, but also
suggests that detection of high risk cases may be possible. Early
diagnosis may also allow treatment with compounds containing DNase1 as
a useful adjunct to conventional treatment with immunosuppressive drugs
(Nature Genetics 2000;25:177-81).
This enzyme is secreted in bodily fluids and tends to be active at
sites of cell destruction. It is responsible for clearing up cellular
debris and does so by chopping up long strands of DNA into short pieces
to facilitate their disposal.
While trying to elucidate some of the processes involved in apoptosis
(programmed cell death), Professor Tarik Mïrïy at the University of
Essen and his colleague Professor Hans-Georg Mannherz at the
Ruhr-University of Bochum produced a "knock out" mouse genetically
engineered to make no DNase1. "Rather surprisingly," said Professor
Mïrïy, "we found an SLE phenotype in the knock out mouse." The
team discovered they had produced mice that became ill at about 6 months, developed glomerulonephritis, and produced antinuclear
antibodies (ANA) characteristic of SLE.
This, together with earlier work that had established a connection
between DNase1 and SLE in humans, suggested that the knock out mice
were developing full blown SLE. This work confirms the role of poor
clearance of cellular debris in SLE and fits in with research that
showed that people with SLE tended to have low serum levels of DNase1.
"If glomerulonephritis and ANA are already present," said Professor
Mïrïy, "it is probably too late for the administration of DNase1
to make much difference." But he does think that if people who are at
high risk of developing the disease can be identified by serum DNase1
levels, then administering the enzyme might be beneficial in reducing
the worse effects of SLE: "I see it as preventive more than
therapeutic." Professor Mark Walport at Hammersmith Hospital agrees
that the link between cellular waste disposal and the development of
SLE is strong. His team studied both C1q (a protein in the complement
system) and serum amyloid P component. Both are implicated in cellular
waste disposal, and a lack of these molecules also seems to trigger the
autoimmune response in SLE.
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.